

## Revenio Group Corporation: Managers' Transactions - Ann-Christine Sundell

**Revenio Group Corporation, Managers' transactions, May 12, 2023 at 5.00 p.m. (EEST)**

### **Revenio Group Corporation: Managers' Transactions - Ann-Christine Sundell**

Person subject to the notification requirement

Name: Ann-Christine Sundell

Position: Member of the Board/Deputy member

Issuer: Revenio Group Oyj

LEI: 743700127E0FWSXLKK04

Notification type: INITIAL NOTIFICATION

Reference number: 31325/6/6

Transaction date: 2023-05-11

Outside a trading venue

Instrument type: SHARE

ISIN: FI0009010912

Nature of transaction: RECEIPT OF A SHARE-BASED INCENTIVE

Transaction details (1):

Volume: 513 Unit price: 0 EUR

Aggregated transactions (1):

Volume: 513 Volume weighted average price: 0 EUR

### **For further information, please contact**

CFO Robin Pulkkinen, tel. +358 50 505 9932

[robin.pulkkinen@revenio.fi](mailto:robin.pulkkinen@revenio.fi)

### **Distribution**

Nasdaq Helsinki

FIN-FSA

Key media

[www.reveniogroup.fi](http://www.reveniogroup.fi)

### **Revenio Group in brief**

Revenio is a leading company in the global market for ophthalmological devices and software solutions. Revenio's ophthalmic diagnostic solutions include intraocular pressure (IOP) measurement devices (tonometers), fundus imaging devices, and perimeters as well as clinical

# REVENIO

---

software under the iCare brand. iCare is a trusted partner in ophthalmic diagnostics, offering physicians fast, easy-to-use, and reliable tools for the diagnosis of glaucoma, diabetic retinopathy, and macular degeneration (AMD). iCare Solutions provide digital clinical tools that drive greater efficiency and enhance quality in eye care.

In 2022, the Group's net sales totaled EUR 97.0 million, with an operating profit of EUR 29.7 million. Revenio Group Corporation is listed on Nasdaq Helsinki with the trading code REG1V.

## Attachments

---

[Revenio Group Corporation: Managers' Transactions - Ann-Christine Sundell](#)